Published on February 13, 2026
–
Updated on February 13, 2026
Dates
on the January 28, 2026
Roca Therapeutics is developing an innovative therapeutic approach for the treatment of uveal melanoma, a rare and aggressive eye cancer for which treatment options remain limited today.
Born out of academic research on the French Riviera and supported by the Université Côte d’Azur Initiative of Excellence, the start-up draws on more than ten years of scientific expertise to design new molecules that target both tumor pathology and the side effects associated with current treatments. With this in mind,
Roca Therapeutics is developing a non-invasive treatment in the form of eye drops, designed to replace heavy and restrictive eye injections.
Its development program includes RCT001, a candidate molecule for the treatment of metastatic forms of uveal melanoma, and RCT002, dedicated to the prevention and treatment of ocular complications induced by proton therapy.
In this context, the drug candidate RCT002 has received Orphan Drug Designation (ODD) for the treatment of radiation maculopathy, now recognized as a distinct disease by the European Medicines Agency (EMA).
Currently in the clinical preparation phase, Roca Therapeutics aims to revolutionize the management of uveal melanoma and pave the way for new therapeutic strategies in ophthalmology.
Read the full article in INSIGHTS magazine No. 3 (pages 42-43).
Roca Therapeutics is developing a non-invasive treatment in the form of eye drops, designed to replace heavy and restrictive eye injections.
Its development program includes RCT001, a candidate molecule for the treatment of metastatic forms of uveal melanoma, and RCT002, dedicated to the prevention and treatment of ocular complications induced by proton therapy.
In this context, the drug candidate RCT002 has received Orphan Drug Designation (ODD) for the treatment of radiation maculopathy, now recognized as a distinct disease by the European Medicines Agency (EMA).
Currently in the clinical preparation phase, Roca Therapeutics aims to revolutionize the management of uveal melanoma and pave the way for new therapeutic strategies in ophthalmology.
Read the full article in INSIGHTS magazine No. 3 (pages 42-43).
